Sutton Debbie, Ovington Susan, Engel Barbara
Wessex Renal and Transplant Unit, Queen Alexandra Hospital, Portsmouth, Hampshire, UK.
J Ren Care. 2014 Sep;40(3):157-63. doi: 10.1111/jorc.12056. Epub 2014 Mar 20.
Constipation is a significant problem for many patients on peritoneal dialysis (PD). Due in part to dietary restrictions it is a common cause of technique failure and poor dialysis efficacy. Both consequences have an economic cost as well as contributing to a poor patient experience.
This study aimed to investigate whether an appropriate daily bowel habit could be achieved through a higher fibre intake, minimal use of laxatives and with no adverse effect on potassium, phosphate and fluid balance.
One hundred and seven patients who had been on PD for at least three months were recruited from seven renal units. They were asked to record daily bowel habits (Bristol Stool Form Scale: BSFS) and laxative use for four weeks. From this group 41 suitable patients with regular laxative use were identified and invited to enter the Intervention stage, Stage 2. Patients were randomised into one of three intervention arms: high fibre supplement (HFS); high fibre diet (HFD) or placebo.
During the intervention stage, intake of HFS increased significantly between week 1 and week 4 (p = 0.04) and in the placebo group between week 1 and week 3 (p = 0.02). There was no significant increase in fibre intake for those on the HFD. Laxative dose appeared to decrease in the HFS group (38%) and the HFD group (16%) but these changes were not significant when compared to the placebo.
This study has confirmed the prevalence of laxative use amongst patients on PD and shown that fibre use can confer improvements in bowel function without affecting biochemistry.
便秘是许多腹膜透析(PD)患者面临的一个重要问题。部分由于饮食限制,它是技术失败和透析效果不佳的常见原因。这两种后果都有经济成本,也会导致患者体验不佳。
本研究旨在调查通过增加纤维摄入量、尽量少用泻药且对钾、磷和液体平衡无不良影响,是否能实现适当的每日排便习惯。
从7个肾脏单位招募了107名接受腹膜透析至少3个月的患者。他们被要求记录四周的每日排便习惯(布里斯托大便形状量表:BSFS)和泻药使用情况。从该组中确定了41名经常使用泻药的合适患者,并邀请他们进入干预阶段,即第二阶段。患者被随机分为三个干预组之一:高纤维补充剂(HFS)组;高纤维饮食(HFD)组或安慰剂组。
在干预阶段,HFS组在第1周和第4周之间摄入量显著增加(p = 0.04),安慰剂组在第1周和第3周之间摄入量显著增加(p = 0.02)。HFD组的纤维摄入量没有显著增加。HFS组(38%)和HFD组(16%)的泻药剂量似乎有所下降,但与安慰剂组相比,这些变化并不显著。
本研究证实了腹膜透析患者中使用泻药的普遍性,并表明使用纤维可以改善肠道功能而不影响生化指标。